H9N2 AIV purified haemagglutinin (HA)

Background

Overview

The haemagglutinin (HA) protein of the H9N2 avian influenza virus (AIV) is a vital component located on the virus's surface, playing a crucial role in the infection process. HA facilitates the entry of the virus into host cells by binding to sialic acid receptors on the cell membrane. This protein is integral to developing various diagnostic tools, vaccines, and therapeutic interventions. In diagnostics, HA is used to create accurate assays for detecting H9N2 infections, as it allows for the identification of the virus through its unique binding properties. For vaccine development, HA helps identify critical epitopes, which are specific regions of the protein that elicit a robust immune response, enabling the design of vaccines that target these key areas to generate adequate immunity. Additionally, HA is instrumental in the creation of targeted antiviral therapies. Designing molecules or agents that specifically block the interaction between HA and sialic acid receptors can prevent the virus from entering host cells, thereby offering potential therapeutic solutions for managing H9N2 AIV infections.

H9N2 AIV Purified Haemagglutinin (HA) Aptamers

H9N2 HA aptamers are highly specific, synthetically engineered molecules designed to target and bind to the HA protein of the H9N2 influenza virus. These aptamers have a range of applications in the management and study of H9N2 AIV, including:

• Diagnostic Tools: H9N2 HA aptamers can be used to develop sensitive and specific diagnostic assays for detecting H9N2 infections. Their ability to bind precisely to the HA protein allows for accurate virus identification, facilitating early detection and monitoring of outbreaks.
• Vaccine Development: H9N2 HA aptamers can help create effective vaccines by identifying and targeting critical epitopes on the HA protein that are essential for eliciting an immune response.
• Therapeutic Research: H9N2 HA aptamers have the potential to design antiviral therapies. By binding to the HA protein, they can inhibit its interaction with host cell receptors, thereby preventing the development of effective treatments for H9N2 AIV. Compared to antibodies, aptamers offer significant advantages in treating viral diseases due to their ability to bind to diverse targets with reduced risk of eliciting an immune response. A key benefit of aptamers is their chemical synthesizability, which stands in contrast to the production of antibodies. This property allows for the targeted development of aptamers to disrupt multiple stages of the viral life cycle by specifically addressing various factors involved.

Fig.1 Scheme of viral life cycle and targets for aptamer.¹

Services

Creative Biolabs provides several anti-H9N2 HA aptamers to advance client projects. These high-quality aptamers are designed to provide robust detection, research, and therapeutic development tools. Each aptamer is engineered for exceptional specificity and affinity for the H9N2 HA protein, ensuring reliable application performance.

Reference

1. Kim, Tae-Hyeong, and Seong-Wook Lee. "Aptamers for anti-viral therapeutics and diagnostics." International Journal of Molecular Sciences 22.8 (2021): 4168.